Synthis Therapeutics, Inc.
New York, NY · Biotech · Private
PTA, a novel combination immunotherapy combining checkpoint inhibitor with TGF-inhibition for colorectal cancer
- Grants
- $3.3M
- 6 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 14
- 3 granted · 11 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20182019202020212022202320242025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Development of a T cell-targeted TGF-b antagonist that reverses immune suppression in melanoma patients | $299,946 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a novel checkpoint inhibitor-TGF beta combination therapy to reverse immune suppression and increase survival rates in advanced colorectal cancer patients | $509,975 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a novel checkpoint inhibitor-TGF beta combination therapy to reverse immune suppression and increase survival rates in advanced colorectal cancer patients | $210,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a targeted TGF-b therapeutic that selectively blocks lung fibrosis in idiopathic pulmonary fibrosis (IPF) patients | $299,900 | |
| Federal grant | Department of Health and Human Services · Phase II · In vivo efficacy, safety and PK/PD analysis of SYN101, a first in class, immune cell targeted TGFb therapy for cancer patients | $578,977 | |
| Federal grant | Department of Health and Human Services · Phase II · In vivo efficacy, safety and PK/PD analysis of SYN101, a first in class, immune cell targeted TGFb therapy for cancer patients | $1,420,853 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3064 | Nested Therapeutics | — | — |
| 3065 | ELSOHLY LABORATORIES, INC. | — | — |
| 3066 | 490 BIOTECH INC | — | — |
| 3067 | Synthis Therapeutics, Inc. | — | — |
| 3068 | Ottimo Pharma | — | — |
| 3069 | Vidasym, Inc | — | — |
| 3070 | Arrowhead Pharmaceuticals | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- ANTIBODY-ALK5 Inhibitor Conjugates And Their Usesapplication
- ANTIBODY-ALK5 Inhibitor Conjugates And Their Usesgranted
- ALK5 Inhibitors And Their Usesgranted
- ALK5 Inhibitor Conjugates And Uses Thereofapplication
- ANTIBODY-ALK5 Inhibitor Conjugates And Their Usesgranted
- ANTIBODY-ALK5 Inhibitor Conjugates And Their Usesapplication
- ANTIBODY-ALK5 Inhibitor Conjugates And Their Usesapplication
- ANTI-CD5 Antibodies And Their Usesapplication
- ALK5 Inhibitor Conjugates And Uses Thereofapplication
- ANTI-CD5 Antibodies And Their Usesapplication
- ANTIB0DY-ALK5 Inhibitor Conjugates And Their Usesapplication
- ANTIBODY-ALK5 Inhibitor Conjugates And Their Usesapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.